An interventional study of Wearable Ultrasound Patch in Breast Cancer, Breast Abnormalities and Breast Lesion, sponsored by Massachusetts General Hospital. Not yet recruiting at 1 site in United States. Open to female participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-21.
Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies in Breast Neoplasms by Massachusetts General Hospital — 12 open to participants now, 23 under way, none of them phase 3. Breast Neoplasms · Massachusetts General Hospital.
Among the 66 studies in Breast Neoplasms by Massachusetts General Hospital, this one is the 28th largest by planned enrollment of the 53 interventional ones that give a count, is one of 2 that started in 2026, is one of 33 with no phase, reaches primary completion later than 4 of the 22 other live ones, and was the 63rd registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →12 of the 66 studies in Breast Neoplasms by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18+ · Women only
Massachusetts General Hospital · Sites in United States
Ages 18–80 · Women only
Massachusetts General Hospital · Sites in United States
Ages 60+ · Women only · Healthy volunteers
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years to 85 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 13 · Phase 4 1
First in 1997; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 51 across the 53 interventional studies, 240 across the 13 observational. Of the 37 that completed or were terminated, 16 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
14 of the studies in Breast Neoplasms by Massachusetts General Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02826434Massachusetts General HospitalAdjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer | 2026-12 |
| NCT03362060Massachusetts General HospitalPVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer | 2026-12-30 |
| NCT03822312Massachusetts General HospitalA Pilot Study of Tomographic Optical Breast Imaging (DBT-TOBI) to Monitor Response to Neoadjuvant Therapy | 2026-12-30 |
| NCT07186491Massachusetts General HospitalWearable Ultrasound Patch for Breast Imaging | 2026-12-31 |
| NCT03945721Massachusetts General HospitalA Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 66 studies in Breast Neoplasms by Massachusetts General Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if a wearable ultrasound (US) patch can provide reliable whole-breast imaging and accurately detect breast lesions in patients undergoing breast health evaluation. The main questions it aims to answer are:
Researchers will compare results from the wearable US-patch to conventional ultrasound to see if the patch provides specific and sensitive findings.
Participants will:
This study is designed to evaluate the performance, safety, and reliability of a newly developed conformable wearable ultrasound (US) patch for whole-breast imaging. The device is a flexible, skin-adherent transducer array that provides real-time, three-dimensional imaging of the breast. The primary goal of the study is to assess the diagnostic accuracy of the US-patch device in detecting breast lesions across a variety of breast shapes, sizes, and tissue densities, using conventional handheld ultrasound as the reference standard (ground truth).
Investigators plan to enroll 50 patients over a 12-month period who are undergoing breast health evaluation and either have had or are scheduled for conventional breast ultrasound within one month. Participants will undergo imaging with the US-patch device, which will be applied directly to the breast and secured with a sports bra to maintain consistent contact. The imaging session will take less than 15 minutes and will be performed by trained study personnel.
The diagnostic performance of the US-patch device will be assessed by calculating sensitivity and specificity for breast lesion detection, using true positive, false positive, true negative, and false negative determinations based on radiologist interpretation. Statistical analyses will be performed on a per-lesion basis. Findings will be compared to conventional ultrasound results to determine the accuracy and reliability of the device.
Safety and tolerability will also be evaluated. All participants will be contacted by telephone one week after the imaging session to assess for any delayed adverse effects. Participants who return for follow-up visits within the one-year study period will undergo repeat US-patch imaging, and any adverse events, discomfort, or skin irritation will be documented.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants in this arm will undergo breast imaging using the wearable ultrasound (US) patch device. The patch is a flexible, skin-adherent transducer array designed to provide whole-breast 3D ultrasound imaging. It will be applied directly to the breast with coupling gel and secured with a sports bra to maintain contact. Imaging will be completed in less than 15 minutes, and results will be compared with conventional ultrasound, which serves as the reference standard.
Device: Wearable Ultrasound Patch
The Wearable Ultrasound Patch is a non-invasive imaging device designed to provide real-time breast imaging (3D) through a flexible, skin-adherent US transducer array. The patch conforms to the natural shape of the breast and allows for continuous and comfortable imaging, reducing patient discomfort and improving diagnostic efficiency. It is intended for use as an adjunct imaging tool for breast health assessment, enabling early detection and follow up of lesions in diverse breast morphologies. Patients will use a newly developed software application named "myFUS" to properly position the US probe on their body. The software application will prompt patients through all the required steps to complete the screening. The first imaging session will be performed by the study personnel with the help of the myFUS application.
Sensitivity and Specificity of the Wearable Ultrasound Patch for Detecting Breast Lesions
The primary outcome will assess the diagnostic accuracy of the conformable US-patch device by comparing its breast lesion detection results to conventional handheld ultrasound (reference standard). Sensitivity and specificity will be calculated per lesion using true positive, false positive, true negative, and false negative determinations based on radiologist interpretation. This metric will serve as the main assessment of the device's performance in detecting breast anomalies across a range of breast shapes, sizes, and tissue densities.
Time frame: From enrollment to 1 week after initial imaging
Safety of the Wearable Ultrasound Patch
The number of participants experiencing adverse effects, discomfort, or skin irritation related to the wearable US-patch device will be recorded. Participants will be contacted by telephone one week after the initial imaging session, and any follow-up imaging visits within the one year study period will also include assessment of safety and tolerability.
Time frame: From enrollment to 1 week after the initial US-patch imaging, and at any follow-up visit within the 12-month study period.
Plan to share: Yes — De-identified participant data will be shared with other researchers for scientific and educational purposes. This may include imaging data from the wearable US-patch device, conventional ultrasound results, and associated clinical and demographic information. No personal identifiers (such as names, contact information, or dates of birth) will be included. Data will be shared under a formal data use agreement to ensure confidentiality and proper use.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: The results should be made public within 24 months of reaching the end of the study. The study's end is the time point at which the last data items are to be reported, or after the outcome data are mature for analysis.
Access criteria: Only members of the MIT-MGB research team will have access to the IPD.
Start is estimated for Sep 2026; primary completion for Dec 2026, 3 months later.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 3 months is below that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Massachusetts General Hospital →